Menu
St. Sulpice, SWITZERLAND, 11th January 2018 – SOPHiA GENETICS, global leader in Data-Driven Medicine, announced today that Valentin Matillon has joined the company’s management team as Chief Financial Officer. He brings over twenty years of experience in senior financial management positions in leading technology organizations, including SITA, Hewlett-Packard and Electronic Arts.
“I am happy to welcome Valentin to our management team,” said Jurgi Camblong, CEO & Co-Founder of SOPHiA GENETICS. “His track record in transforming finance functions and supporting new acquisitions, along with his pragmatic and results-driven approach, make him a natural fit for the fast-paced culture of SOPHiA GENETICS.”
This management change comes at an important time as the company ramps up its efforts to conquer new markets and develop innovative Data-Driven Medicine solutions. SOPHiA AI, the clinicians’ technology of choice for genomic analysis, is being used by over 400 healthcare institutions across 55 countries. It is paving the way towards a Collective Intelligence, and currently helps to diagnose a patient every 5 minutes. SOPHiA GENETICS’ approach was recognized by the MIT Technology Review who ranked it amongst the 50 Smartest Companies in 2017.
“I am proud to take over the role of CFO of SOPHiA GENETICS. Our groundbreaking technology and approach are revolutionizing the healthcare field, improving the prognosis of patients worldwide. I look forward to supporting the company through its journey of growth and development. This is a unique opportunity to play a part in history being made.” – Valentin Matillon
Valentin joins SOPHiA GENETICS from the Hobart Group where he served as Senior Director of Finance. Valentin was previously Senior Director, Corporate Finance and Performance Management, at SITA. Prior to that, he held Finance roles at Electronic Arts and Hewlett-Packard Europe. Valentin holds a BBA degree from the Institute des Hautes Etudes Economiques et Commerciales de Paris, and an MSc in Technology and Management from the Ecole centrale de Paris.
Valentin will be responsible for the company’s Finance and Accounting functions, previously managed by Marylin Mermod Schule who held the dual roles of CFO and Chief Operations Officer. Going forward, Marylin will fully dedicate her expertise to leading the company’s operations initiatives, and sustaining the international expansion of the group.
“I would like to thank Marylin for the outstanding contributions she has made as CFO of the company”, said Jurgi Camblong. “Since 2015, Marylin has led financial operations, built the accounting function, and successfully managed two fundraising series. I look forward to the impact she will make as she focuses solely on driving our operational management and development.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
